Delivery of Allergen Powder for Safe and Effective Epicutaneous Immunotherapy.
More effective and safer immunotherapies to manage peanut allergy are in great demand despite extensive investigation of sublingual/oral (SLIT/OIT) and epicutaneous (EPIT) immunotherapies currently in the clinics. To develop a powder-laden, dissolvable microneedle array (PLD-MNA) for epidermic delivery of powdered allergens and to evaluate efficacy of this novel EPIT in peanut-sensitized mice. PLD-MNA was packaged with a mixture of powdered peanut allergen (PNA), vitamin-D3 (VD3), and CpG. Its epidermic delivery and therapeutic efficacy were evaluated, alongside PNA-specific Foxp3+T regulatory (Treg) cells and IL-10+ and TGF-β1+ skin-resident macrophages. PLD-MNA was successfully laden with PNA/VD3/CpG powder and capable to epidermically deliver most of its content one hour after applied onto intact mouse skin, concomitant with no significant leakage into the circulation or skin irritation. PLD-MNA-mediated EPIT substantially reduced clinical allergy scores to 1, from 3.5 in sham controls (p<0.001) after six treatments, accompanied with lower levels of PNA-specific IgE and intestinal mucosal mast cells and eosinophils over sham treatments. Moreover, in comparison with allergens intradermally administered, powdered allergens delivered by PLD-MNA preferentially attracted immunoregulatory macrophages and stimulated the cells to produce IL-10 and/or TGF-β at the immunization site, which may account for increased numbers of Treg-like cells in lymph tissues in association with systemic tolerance. PNA/VD3/CpG-laden PLD-MNA was safe and required only six treatments and one fifth of the PNA-adjuvant dose with improved outcomes, when compared to twelve conventional intradermal immunotherapies. PLD-MNA holds great promise as a novel, safe, effective, and self-applicable modality to manage IgE-mediated allergies.